Clinical trial
A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus…
NCT00322049 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00322049 |
|---|---|
| Title | A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants |
| Official title | A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Dengue |
| Intervention type | Biological |
| Interventions | Tetravalent live attenuated dengue vaccine, Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine |
| Enrollment | 51 |
| Start date | Feb 1, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | May 4, 2006 |
| Last update posted | Jan 19, 2018 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: